Challenges Facing Physicians Treating Cardiac and Vascular Diseases
There are very few low cost, non invasive, clinical solutions for Congestive Heart Failure (CHF) patients and patients suffering with vascular diseases such as Peripheral Artrial Disease (PAD). Physicians currently have no effective means by which to treat these patients outside of the clinical setting, i.e. in the home environment.

Approximately 23 million people worldwide are afflicted with Congestive Heart Failure (CHF), and 2 million new cases of CHF are diagnosed each year worldwide. In the U.S., $20 billion was spent on Heart Failure patients. In contrast to other cardiovascular disorders that have declined during the past few decades, the incidence of Heart Failure is on the rise. It is the most rapidly growing cardiovascular disorder in the United States and other developing countries, such as India.

Peripheral Arterial Disease (PAD) is becoming more prevalent in the patient population and is associated with high rates of myocardial infarction, stroke, amputation and death. A total of $4.37 billion was spent in the U.S. on PAD related treatments, 88% of which was used for inpatient care. In the U.S., 6.8% of the elderly Medicare population received treatment for PAD. There are 8 million patients in the U.S. with PAD and an estimated 40 million worldwide.

Virum’s Unit Allows Physicians to Cost
Effectively Treat CHF and Vascular Patients
Virum has developed a low cost, home-based therapy for the treatment of CHF and PAD.

The unit is low cost, non-invasive, home-based therapy, which can be programmed to each patient’s specific requirements. The programming of the unit is based on a patented measurement technology and requires a physician to write the necessary prescription.

Treating patients at home and decreasing their rehospitalization will significantly reduce the current healthcare cost of the CHF patient population. In a Congestive Heart Failure study (Vijay, et al.) it was demonstrated that this methodology reduced rehospitalization by over 80% in the year after receiving this therapy.

The unit promotes the revascularization of areas in the heart and peripheral circulation with poor perfusion, thus restoring a dynamic blood flow and movement towards healthy vasculature.

The system is user friendly and easily operated by the patient. The system can be used while the patient is watching television, reading, or relaxing (for at least one hour).

Clinically Proven Technology and Patient Studies
Virum has an exclusive licensing agreement with Cardiomedics, Inc., a leading cardiology company, for the use of its core technology. The initial Cardiomedics technology was developed at Harvard and M.I.T., is FDA approved and has Medicare reimbursement. This core technology has been enhanced and developed by Virum for the specific home application.

The treatment methodologies utilized by Virum home unit have been clinically proven in multiple published, peer reviewed journals and is patent protected.